Pharmacometric modeling and machine learning analyses of prognostic and predictive factors in the JAVELIN Gastric 100 phase III trial of avelumab

Avelumab (anti–PD‐L1) is an approved anticancer treatment for several indications. The JAVELIN Gastric 100 phase III trial did not meet its primary objective of demonstrating superior overall survival (OS) with avelumab maintenance versus continued chemotherapy in patients with advanced gastric canc...

Descripción completa

Detalles Bibliográficos
Autores principales: Terranova, Nadia, French, Jonathan, Dai, Haiqing, Wiens, Matthew, Khandelwal, Akash, Ruiz‐Garcia, Ana, Manitz, Juliane, von Heydebreck, Anja, Ruisi, Mary, Chin, Kevin, Girard, Pascal, Venkatakrishnan, Karthik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8923733/
https://www.ncbi.nlm.nih.gov/pubmed/34971492
http://dx.doi.org/10.1002/psp4.12754

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8923733/
https://www.ncbi.nlm.nih.gov/pubmed/34971492
http://dx.doi.org/10.1002/psp4.12754

Ejemplares similares